Living Well With Advanced Breast Cancer
Part of paid clinical trials in Columbus, Ohio.
- Sponsor
- Ohio State University Comprehensive Cancer Center
- Study ID
- NCT07227038
- Status
- Recruiting
Conditions
- Advanced Breast Carcinoma
- Anatomic Stage IV Breast Cancer AJCC v8
- Metastatic Breast Carcinoma
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Accepted
Interventions
- Non-Interventional Study — OTHERNon-interventional study
Study Details
This study evaluates the use of supportive care in patients with advanced breast cancer to better understand what has helped them, what has been hard, and what kind of help they still need.
Key Dates
- Start date
- Jan 13, 2026
- Status verified
- Mar 2026
- Primary completion
- Dec 31, 2026
- Completion
- Dec 31, 2026
Study Design
- Enrollment
- 50 participants (estimated)
Arms
- Arm: ObservationalPatients complete a survey and a semi-structured interview on study.
Primary Outcome Measure
Acceptability of current LWABC (Living Well with Advanced Breast Cancer) model [ Time Frame: Up to study completion, up to 1 day ]
Central Contacts
- The Ohio State University Comprehensive Cancer Center800-293-5066
Locations (1)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| Ohio State University Comprehensive Cancer Center | Columbus | Ohio | 43210 | Ashley P. Davenport, MD (PRINCIPAL_INVESTIGATOR) |
Find similar trials in Columbus, OH
By research site
Related Studies
- Testing the Addition of an Individualized Vaccine to Durvalumab and Tremelimumab and Chemotherapy in Patients With Metastatic Triple Negative Breast CancerPHASE2 · Recruiting · National Cancer Institute (NCI) · Orange, California
- S1703 Serum Tumor Marker Directed Disease Monitoring in Patients With Hormone Receptor Positive Her2 Negative Metastatic Breast CancerRecruiting · SWOG Cancer Research Network · Anchorage, Alaska
- Topical or Oral Minoxidil for the Treatment of Endocrine Therapy-Induced Alopecia in Patients With Stage I-IV Breast CancerEARLY_PHASE1 · Recruiting · Ohio State University Comprehensive Cancer Center · Columbus, Ohio
- Testing the Addition of Anti-Cancer Drug, ZEN003694 (ZEN-3694) and PD-1 Inhibitor (Pembrolizumab), to Standard Chemotherapy (Nab-Paclitaxel) Treatment in Patients With Advanced Triple-Negative Breast CancerPHASE1 · Recruiting · National Cancer Institute (NCI) · Boston, Massachusetts